NATICK, Mass., April 3, 2025 /PRNewswire/ -- Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced they have received nationwide Medicare coverage by the Centers for Medicare & ...
Seekin Inc.’s cancer mutation detection kit Pancanseek for leukemia patients has received a CE-IVD mark, expanding the company’s reach in the testing space. This kit uses high-depth whole-genome ...
Company continues to execute on its global strategy to bring highly accurate and sensitive NGS cancer diagnostics to enable localized testing "We are pleased to have expanded the clinical utility of ...
Illumina raised the curtain on a revamp of its flagship tumor profiling test, which aims to offer faster turnarounds, fewer materials and fuller coverage of difficult genomic regions with the goal of ...
The AVENIO Tumor Tissue Comprehensive Genomic Profiling (CGP) Kit is the first jointly-developed product that brings together the expertise and reach of Roche with Foundation Medicine’s pioneering ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, and Gencurix, Inc. (KOSDAQ: 229000), a leading Korean developer of ...
NATICK, Mass., Dec. 1, 2025 /PRNewswire/ -- Pillar Biosciences, the leader in Decision Medicine™, today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized its pricing ...
Company also has a lung cancer test in development. Epigenomics confirmed the European launch of Epi proColon, reportedly the first CE-marked IVD blood test for detecting colorectal cancer. The ...
NATICK, Mass., Oct. 24, 2024 /PRNewswire/ -- Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced that they have been granted a unique CPT® Proprietary Laboratory Analyses (PLA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback